Vaxcyte, Inc. (PCVX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 9.67B USD. 52-week range 39.87 to 90.75 USD. Data as of 2026-10-09.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel ...